GlobeNewswire Inc.··Not SpecifiedFulcrum Therapeutics Advances Sickle Cell Program With Positive Data, Eyes 2029 Runway
Fulcrum Therapeutics reports positive pociredir data in sickle cell disease, plans registration trial in H2 2026, maintains $333.3M cash runway through 2029.
FULCclinical trialFDA